The window Fort Worth has been waiting on is almost open.
Fort Worth has built a quieter and arguably more grounded longevity market than its larger neighbor across the Metroplex. The medical district that anchors the Cultural District and runs west toward the JPS Health Network and Texas Health Harris Methodist campus has decades of established endocrinology and primary-care practice. Concierge and direct-primary-care models are well represented in the western suburbs — Mira Vista, Westover Hills, the TCU corridor — and these practices have been quietly running bioidentical hormone protocols and selected compounded peptide work for years. What is changing now is the federal regulatory frame around growth-hormone-axis peptides.
The short version: in 2023 the FDA placed several named peptides — including BPC-157, KPV, TB-500, MOTs-C, and others — into Category 2 of the 503A bulk substances list, which restricts but does not prohibit compounding. On April 16, 2026 a Federal Register notice reopened the nominations process. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to review the science and vote on whether those compounds move into Category 1 (clearly compoundable under 503A) or stay in Category 2. Whatever the committee decides, the Fort Worth providwrs preparing for that meeting are about to be in a very different position than they were a year ago.
Texas remains a steady regulatory environment for this work. The Texas State Board of Pharmacy permits 503A compounding for individual patient prescriptions, and the Texas Medical Board has treated bioidentical hormone work and peptide therapy as practice-of-medicine questions for the physician-patient relationship. Fort Worth endocrinology and longevity practices have continued to work with licensed compounding pharmacies through the Category 2 period. Find Peptide Clinics exists to make that legitimate, licensed lane easy to find — and to make the gray-market storefronts easy to avoid.